Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1CNS 1

Conditions

Ovarian Neoplasms 7Glioblastoma 4Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Rare Tumour 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoadjuvant Therapy 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Locally Advanced Prostate Cancer 1Limited Stage Small Cell Lung Cancer 1Hereditary leiomyomatosis and renal cell cancer 1HER2-negative Breast Cancer 1Gliosarcoma 1Glioma 1For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinosarcoma 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × pamiparib × Clear all
NCT03150862 2025-02-04

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

BeiGene

Phase 1/2 Completed
116 enrolled 31 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Nervous System Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Gliosarcoma

NCT04985721 2023-03-15

IMPARP-HRD

Peter MacCallum Cancer Centre, Australia

Phase 2 Unknown
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡